Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma
Patients with no objective clinical response to induction chemotherapy.
\> 25% bone marrow infiltration following induction chemotherapy.
Platelets \< 100,000 before radioimmunotherapy.
Severe and/or uncontrolled concomitant disease:
Hepatic, renal, cardiovascular, neurological or metabolic disease.
Cardiac failure, ischemic cardiopathy, ischemic cardiopathy with a history of myocardial infarction or angor, or major ventricular arrhythmia.
Positive regarding HBV, HCV, HIV.
Active acute or chronic infection.
Social, psychic or geographic disability to satisfy any of the treatment schemes.
Pregnant and/or breastfeeding women, or adult patients of childbearing age who are not using a safe birth control device throughout the study treatment and at least 12 months thereafter.
Known or suspected hypersensitivity, or confirmed or suspected adverse reaction to the study drugs and other related compounds (Rituximab, Ibritumomab tiuxetan, a history of sensitivity to murine proteins, dexametasone, cyclophosphamide and other anthracyclines, cytarabine).
Clareo Health | Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma
